Mosaic ImmunoEngineering (CPMV) Long-Term Deferred Tax (2013 - 2020)
Mosaic ImmunoEngineering (CPMV) posted quarterly Long-Term Deferred Tax of $52156.0 for Q3 2019, little changed year-over-year from $52156.0 in Q3 2018, and down 99.29% quarter-over-quarter from $7.3 million in Q2 2019.
Mosaic ImmunoEngineering (CPMV) Long-Term Deferred Tax (2013 - 2020) Analysis & Trends
Mosaic ImmunoEngineering's Long-Term Deferred Tax history runs 4 years deep, the most recent figure standing at $52156.0 for Q3 2019.
- In Q3 2019, Long-Term Deferred Tax changed 0.0% year-over-year to $52156.0; the TTM figure through Aug 2019 stood at $52156.0 (changed 0.0% YoY), while the FY2019 annual figure was $7.3 million, up 13955.86% from the prior year.
- Long-Term Deferred Tax for Q3 2019 stood at $52156.0, down from $7.3 million in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $7.3 million in Q2 2019, with the low at $52156.0 in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Mosaic ImmunoEngineering | 3.68 Mn | 3.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2020 | 7.69 Mn |
| Aug 31, 2019 | 52,156.00 |
| May 31, 2019 | 7.33 Mn |
| Feb 28, 2019 | 52,156.00 |
| Nov 30, 2018 | 52,156.00 |
| Aug 31, 2018 | 52,156.00 |
| May 31, 2018 | 52,156.00 |
| Feb 28, 2018 | 52,156.00 |
| May 31, 2014 | 9.16 Mn |
| May 31, 2013 | 9.49 Mn |